AzTrials
AzTrials

Non-communicable Diseases (NCD)H4HNCT07743021

Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data

An observational study of Non-communicable Diseases (NCD) and Neoplams, run by Center for Molecular Fingerprinting Research Nonprofit LLC at 33 sites in Hungary.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants. Read more about this study

Who is it for?
Ages 40 years and olderHealthy volunteers can take part
Conditions the study is for
Non-communicable Diseases (NCD), Neoplams, Cancer
How many people
15,000 participants
Where
33 sitesHungary
Study dates
27 Jul 2021to 31 Dec 2030
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Study population include healthy participants who are managed by primary healthcare professionals in Hungary, in any parts of the country.

Who may be able to join

  • Signed informed consent form (ICF) of the study.
  • Age > 40 years.
  • Willingness to fill in the study questionnaire.
  • No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.
  • Willingness to participate in future visits.
  • Signed informed consent form (ICF) of the study.
Show all 13Show fewer
  • Age > 50 years.
  • Willingness to fill in the study questionnaire.
  • Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7):
  • Hypertension, receiving antihypertensive treatment.
  • Dyslipidemia/ Hypercholesterolemia (>5.2mmol/L total cholesterol level), on or not on statin-treatment.
  • Active or former smoker, with smoking history of at least 20 pack-years, and/or the presence of intermediate lung nodule on prior LDCT testing.
  • No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented.

Who cannot join

  • Self-reported pregnancy (no test).
  • Indications of clinically relevant medical conditions in self-reported healthy subjects.
  • Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.
  • Any conditions preventing blood-draw.
  • Vulnerable subjects.
  • Foreseeable lack of compliance.
Show all 22Show fewer
  • Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.
  • Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and / or further pharmaceutical product administration is planned.
  • Vaccination within the last 14 days.
  • High-risk Cohort:
  • Self-reported pregnancy (no test).
  • Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD [implantable cardioverter defibrillator] or pacemaker therapy).
  • Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4.
  • Active cancer or malignant disease with less than 5 years history of remission.
  • Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications).
  • Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.
  • Any conditions preventing blood-draw or CT scans.
  • Vulnerable subjects.
  • Foreseeable lack of compliance.
  • Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits.
  • Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and/or further pharmaceutical product administration is planned.
  • Vaccination within the last 14 days of sample collection.

Trial locations and contacts

33 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Center for Molecular Fingerprinting contact

+36 30 084 7359

info@h4h.hu

33 sites in 1 country

Hungary33 sites, 21 recruiting
  • 04_DRC Balatonfüred_Drug Research Center LLC

    Balatonfüred, 8230

    Suspended
  • 14_TP Békéscsaba_Trial Pharma LLC Békéscsaba

    Békéscsaba, 5600

    14_TP Békéscsaba, +36 20 398 2923, akiszabo@gportal.hu

    Recruiting
  • 31_TP Szt Magdolna_Trial Pharma Ltd. Magdalene Private Hospital

    Budapest, 1023

    31_TP Szt Magdolna, +36 1 733 3444, recepcio@szentmagdolna.com

    Recruiting
  • 08_Qualiclinic Budapest_Qualiclinic LLC

    Budapest, 1036

    08_Qualiclinic Budapest, +36 80 496 050, info@qclinic.hu

    Recruiting
  • 22_MÁV Budapest_Railway Health Care Nonprofit Public Benefit Ltd.

    Budapest, 1062

    22_MÁV Budapest, +36 1 881 0100, info@vasuteu.hu

    Recruiting
  • 07_SE Budapest_Semmelweis University, Occupational Health Service

    Budapest, 1085

    Active, not recruiting
  • 01_OVSZ Budapest_Hungarian National Blood Transfusion Service, Central Hungarian Regional Blood Transfusion Center

    Budapest, 1113

    Suspended
  • 20_TP Budapest_Trial Pharma LLC Budapest

    Budapest, 1119

    Active, not recruiting
  • 32_OrthoSera_OrthoSera Medical Zrt.

    Budapest, 1123

    31_OrthoSera, +36 70 770 7298, info@orthosera.com

    Recruiting
  • 11_UNO Med Budapest_UNO MEDICAL TRIALS LLC

    Budapest, 1152

    Active, not recruiting
  • 23_MÁV Miskolc_Hungarian State Railways Clinic in Miskolc

    Budapest, 3527

    23_MÁV Miskolc, +36 46 505 023, info@h4h.hu

    Recruiting
  • 19_TP Csorna_Trial Pharma LLC Csorna

    Csorna, 9300

    Suspended
  • 09_Derma-B Debrecen_DERMA-B LLC

    Debrecen, 4031

    Active, not recruiting
  • 05_DE Debrecen_University of Debrecen Clinical Centre, Institute for Primary Care and Health Promotion of Debrecen

    Debrecen, 4032

    Active, not recruiting
  • 36_CRU Encs_CRU Hungary Healthcare and Service Provider LLC.

    Encs, 3860

    36_CRU Encs, +36 46 798 262, info@cruint.com

    Recruiting
  • 13_TP Győr_Trial Pharma LLC Győr

    Győr, 9026

    Suspended
  • 16_TP Gyula_Trial Pharma LLC Gyula

    Gyula, 5700

    16_TP Gyula, +36 20 824 4122, akos.szabo@smedical.hu

    Recruiting
  • 34_BKS Hatvan_BKS Research Ltd. Albert Schweitzer Hospital and Outpatient Clinic

    Hatvan, 3000

    34_BKS Hatvan, +36 37 341 033, korhaz@askhatvan.hu

    Recruiting
  • 33_TP Fitt Harmony_Fitt Harmony Ltd

    Jászszentlászló, 6133

    33_TP Fitt Harmony, +36 20 404 6095, info@h4h.hu

    Recruiting
  • 28_Kaposvár Kh_Somogy County Kaposi Mór Teaching Hospital

    Kaposvár, 7400

    28_Kaposvár Kh, +36 82 501 300, korhaz@kmmk.hu

    Recruiting
  • 30_TP Kék Pont Kecskemét_Blue Point Aquatherapy Ltd. (KomplexLabor site)

    Kecskemét, 6000

    28_TP Kék Pont Kecskemét, +36 30 088 7333, vervetel.info@gmail.com

    Recruiting
  • 39_TP Kecskemét_Trial Pharma Ltd. Kecskemét

    Kecskemét, 6000

    39_TP Kecskemét, +36 20 404 6095, info@h4h.hu

    Recruiting
  • 26_BAZ Miskolc_Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital

    Miskolc, 3526

    26_BAZ Miskolc, +36 46 515 200 ext. 11846, sajtoreferens@bazmkorhaz.hu

    Recruiting
  • 21_TP Nyíregyháza_Trial Pharma LLC Nyíregyháza

    Nyíregyháza, 4400

    Active, not recruiting
  • 15_TP Orosháza_Trial Pharma LLC Orosháza

    Orosháza, 5900

    Active, not recruiting
  • 25_DermaMed_DermaMed Research LCC.

    Orosháza, 5900

    25_DermaMed, +36 30 665 6711, dermamed.research@gmail.com

    Recruiting
  • 38_Ganglion Orvosi Központ Nozologen Kft._Ganglion Medical Center

    Pécs, 7621

    38_Ganglion Orvosi Központ Nozologen Kft, +36 30 539 2825, info@ganglion.hu

    Recruiting
  • 02_PTE Pécs_University of Pécs, Centre for Occupational Health and Hygiene of the University of Pécs Clinical Centre

    Pécs, 7624

    Active, not recruiting
  • 18_TP Sopron_Trial Pharma LLC Sopron

    Sopron, 9400

    18_TP Sopron, +36 20 960 9400, diag@newmed.hu

    Recruiting
  • 37_KomplexLabor_KomplexLabor Diagnostics Ltd.

    Szeged, 6724

    37_KomplexLabor, +36 62 770 777, info@komplexlabor.hu

    Recruiting
  • 17_TP Szeged_Trial Pharma LLC Szeged

    Szeged, 6726

    17_TP Szeged, + 36 305 195 018, h4h2szeged@gmail.com

    Recruiting
  • 24_MÁV_Szeged_Hungarian State Railways Clinic in Szeged

    Szeged, 6726

    24_MÁV_Szeged, +36 62 548 055, info@h4h.hu

    Recruiting
  • 03_VVM Veszprém_Vita Verum Medical LLP

    Székesfehérvár, 8000

    03_VVM Veszprém, +36 22 999 555, info@doktorplusz.com

    Recruiting

Other trials in Hungary

About this study

Official title: Health for Hungary - Longitudinal Collection of Blood Samples and Corresponding Data for Longterm Evaluation of Innovative Diagnostic Techniques in Subjects Without Clinically Relevant Disorders at Baseline to Institute Molecular Fingerprinting Reference Norms

The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.

Indications Studied:

Read more

Apparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).

Study Design:

Single-country, multicenter, prospective, longitudinal survey.

Objectives:

The study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.

The study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.

Read the detailed description

BACKGROUND

The H4H study monitors health changes for 10 years in participants who are healthy at the outset but are at risk to develop new-onset health conditions. It uses a prospective study design and encompasses over 100,000 person-years of follow-up, allowing close observation of disease trajectories in relation to risk factors and medication use. This provides a unique opportunity to collect data on current tendencies in non-communicable disease (NCD) presentation and management.

Major NCDs (i.e., cardiovascular disease, cancer, type 2 diabetes and chronic respiratory disease) cause a significant loss in quality of life and are responsible for over 90 percent of Hungary's all-cause mortality. Therefore, there is growing demand for screening tools that might be used at minimal expense to reduce the overall burden of diseases. 'Early diagnosis' and recognition of high-risk states prior to the development of overt clinical diseases would allow better therapeutic outcomes and help preserve quality of life longer in the society.

Blood tests are valuable screening tools for many conditions and may be used for population health monitoring. Better understanding of blood composition, along with establishing reference ranges for blood constituents, is essential for developing effective blood-based health monitoring strategies.

High-information-content detection methods, including molecular fingerprinting, proteomics and metabolomics are expected to promote the discovery of novel disease biomarkers. By assessing a wide range of molecules, multiple disease-specific variables may be recognized.

Apart from multimodal analysis of blood samples, aliquots of all samples are preserved in a dedicated biobank with a commitment to accommodate a comprehensive collection of biospecimens for decades and to facilitate long-term research arrangements with the intention to accelerate future discoveries.

OBJECTIVES

The study aims to address the following objectives:

  1. Establish reference ranges for infrared molecular fingerprinting and other high-information-content analysis methods (i.e., proteomics and metabolomics) in a non-symptomatic population using a cross-sectional approach.
  2. Define characteristics of healthy aging and establish personalized reference intervals for infrared molecular fingerprinting and other high-information-content analysis methods using a longitudinal approach.
  3. Identify novel biomarkers for non-communicable diseases, including coronary artery disease, lung cancer and diabetes, using infrared molecular fingerprinting and other high-information-content analysis on blood samples.
  4. Identify novel blood-based risk factors for non-communicable diseases and discover indicators of precursor diseases using infrared molecular fingerprinting and other high-information-content analysis methods.

The findings of the current study will be instrumental in identifying disease specific deviations of human blood composition. This could lead to the discovery of 'novel biomarkers'.

Overall, the study will determine whether the molecular composition of human plasma remains stable over time and will test whether deeper analysis of blood samples can form the basis of population health monitoring.

STUDY DESIGN

The project is conducted in a single-country, multicenter, prospective, longitudinal format. Sample collection is scheduled for ten years according to this protocol.

PARTICIPANTS

The study enrolls healthy subjects of > 40 years or > 50 years in low- or high-risk cohorts, respectively, who are followed up for ten years. Enrollment continues until 15,000 subjects are enrolled.

PROCEDURES:

Blood sample collection occurs in accordance with the clinical routine and plasma samples are processed for high-information-content analysis. Additional blood tubes are submitted to clinical laboratory testing. Health data collection utilizes self-report questionnaires and review of medical records.

In the high-risk cohort, a comprehensive medical examination is performed after the first 4 blood samples are collected, including screening tests for lung cancer and coronary artery disease, i.e., a low-dose CT scan of the chest and coronary artery calcium score test (heart scan). These investigations are repeated after a follow-up period of 5 years.

WITHDRAWAL OF CONSENT, DISCONTINUATION FROM THE STUDY

Participation in this sample and data collection project is voluntary, and each participant has the right to withdraw their consent at any time without any consequence concerning possible future treatment or future blood donations.

Keywords
Personalized health, Molecular fingerprints, Longitudinal health monitoring, Early-stage disease detection, Innovative research platforms, Precision care, Proteomics, Metabolomics, in vitro diagnostics, Prevention medicine
Medical subject headings
Noncommunicable Diseases, Neoplasms, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Cardiovascular Diseases, Atherosclerosis, Peripheral Arterial Disease, Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07743021
Study groupRoleWhat they receive
Low- and moderate-risk cohortApparently healthy, self-reportedly asymptomatic participants aged 40 years or more, who have 0-2 modifiable cardiovascular risk factors (hypertension, hypercholesterolemia, smoking)
High-risk CohortApparently healthy, self-reportedly asymptomatic participants, aged 50 years or more, who have 2(+) modifiable cardiovascular risk factors (hypertension, hypercholesterolemia, smoking)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Healthy aging

    Reference ranges of blood parameters are defined that are associated with healthy aging (participants who do not develop any health conditions during the respective follow-up period). Populational normal ranges are established for the cohort and person-specific reference ranges are explored.

    Measured: 10 years

  2. Coronary artery disease

    Incidence of coronary artery disease is followed up with the aim to identify novel biomarkers of new-onset coronary artery disease based on parameters measured with high information content analytical methods.

    Measured: 10 years

  3. Lung cancer

    Incidence of lung cancer is followed up with the aim to identify novel biomarkers of new-onset lung cancer based on parameters measured with high information content analytical methods.

    Measured: 10 years

  4. Type 2 Diabetes

    Incidence of type 2 diabetes is observed with the aim to identify novel biomarkers of new-onset diabetes based on parameters measured with high information content analytical methods.

    Measured: 10 years

Secondary outcomes (1)
  1. Molecular fingerprints

    Molecular fingerprints acquired from plasma samples.

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2026
  2. Study start27 Jul 2021
  3. Primary completion31 Dec 2030 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
15,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07743021
Sponsor's protocol ID
H4H_HU_2020_Sample Collection
Acronym
H4H
Status last verified
Jul 2026
First submitted
29 Jul 2026
Last updated
3 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in